SELLAS Life Sciences Group, Inc. (SLS) Financial Statements
SELLAS Life Sciences Group, Inc. (SLS) reported trailing twelve-month revenue of $0 (up 0.0% year on year) and net income of -$32.5M as of 2026-06-30, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SLSSELLAS Life Sciences Group, Inc.Follow SLS — free
—
Price chart with a free account
- Market cap
- 2.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & development | 3.9 | 14.6 | 20.4 | 27.7 | 23.6 | 11.4 | 6.1 | 8.8 | 7.3 | 9.3 | 15.7 | 20.3 | 24.0 | 19.1 | 16.0 | 20.3 | |
| Operating income | — | — | -28.5 | -43.9 | -34.2 | -16.0 | -23.0 | — | -20.0 | -17.0 | -25.3 | -42.0 | -37.9 | -31.5 | -28.3 | -35.2 | |
| Pre-tax income | -3.4 | -34.4 | -70.3 | -28.3 | -38.6 | -11.1 | -23.5 | -29.0 | -19.4 | -16.8 | -20.9 | -41.3 | -37.3 | -30.9 | -26.9 | -32.5 | |
| Income tax | — | -1.1 | 1.1 | 0.0 | 0.4 | 0.0 | 0.3 | -1.4 | -0.1 | -0.0 | -0.2 | 0.0 | 0.0 | 0.0 | 0.0 | — | |
| Net income | -11.5 | -35.0 | -76.7 | -36.6 | -63.9 | -17.7 | -23.8 | -27.7 | -19.3 | -16.8 | -20.7 | -41.3 | -37.3 | -30.9 | -26.9 | -32.5 | |
| Diluted EPS ($) | -0.32 | -0.56 | -0.85 | -6.13 | -8.23 | -18.66 | -10.44 | -157.72 | -10.92 | -2.11 | -1.34 | -2.13 | -1.34 | -0.50 | -0.25 | -0.17 | |
| Diluted shares (mn) | — | — | — | — | — | — | — | — | — | — | 15.5 | 19.4 | 27.8 | 61.2 | 109.1 | — |
USD millions · SEC XBRL
SELLAS Life Sciences Group, Inc. — questions
- What is SELLAS Life Sciences Group, Inc.'s revenue?
- $0 over the twelve months to 2026-06-30, up 0.0% year on year, from its 10-Q and 10-K filings.
- What is SELLAS Life Sciences Group, Inc.'s net income?
- -$32.5M over the twelve months to 2026-06-30.
- What are SELLAS Life Sciences Group, Inc.'s diluted earnings per share?
- $-0.17 over the twelve months to 2026-06-30.
Every figure on this page comes from SELLAS Life Sciences Group, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.